International Journal of Leprosy and Other Mycobacterial Diseases - A Mycobacterium leprae isolate resistant to dapsone, Rifampin, Ofloxacin and Sparfloxacin
December 1, 2000 -- A Mycobacterium leprae Isolate Resistant to Dapsone, Rifampin, Ofloxacin and Sparfloxacin1 Since dapsone (DDS) was introduced for leprosy treatment,...
Healthfacts - Antibiotics implicated in recent outbreaks
January 1, 2006 -- Nearly all antibiotics can cause pseudomembranous colitis in a small minority of people. Its severity can range from mild to life-threatening. Only...
Drug Store News - Mylan discontinues Zagam
March 5, 2001 -- Mylan Laboratories is discontinuing the fluoroquinolone antibiotic Zagam (sparfloxacin), which is manufactured by Aventis. Mylan licensed Zagam from...
British Medical Journal - Risk of torsades de pointes with non-cardiac drugs
January 6, 2001 -- Prolongation of QT interval is probably a class effect of fluoroquinolones EDITOR--Yap and Camm emphasise the risk of torsades de pointes...
Photochemistry and Photobiology - Photogenotoxicity of fluoroquinolones in Chinese hamster V79 cells: Dependency on active topoisomerase II
March 1, 1999 -- Received 22 September 1998; accepted 7 December 1998 ABSTRACT The Chinese hamster V79 lung cell in vitro micronucleus assay was adapted to detect...
China Chemical Reporter - Forthcoming Breakthrough in the Domestic Cyclopropylamine Market.
October 26, 1998 -- Cyclopropylamine is mainly used to produce new generation fluorine-containing quinolone broad-spectrum antibiotics such as cinrofloxacin,...
Business Wire - Mylan Announces Acquisition of U.S. Rights to Zagam
August 26, 1998 -- PITTSBURGH--(BUSINESS WIRE)--August 26, 1998--Mylan Laboratories Inc. (NYSE:MYL) announced today that it has acquired from Rhone-Poulenc Roret...
